Want to see STVN full AI Analyst Report?
STVN Stock Chart & Stats
$19.68
$0.21(1.07%)
At close: 4:00 PM EDT
$19.68
$0.21(1.07%)
Day’s Range― - ―
52-Week Range$12.89 - $28.00
Previous CloseN/A
Volume32.66K
Average Volume (3M)315.44K
Market Cap
$6.10B
Enterprise Value$5.35K
Total Cash (Recent Filing)$83.58M
Total Debt (Recent Filing)$442.99M
Price to Earnings (P/E)40.3
Beta0.85
Next Earnings
Nov 10, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,709,717
10 Day Avg. Volume256,276
30 Day Avg. Volume315,443
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.00Price Target Upside16.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.61
Revenue Forecast (FY)$1.27B
Bulls Say, Bears Say
Bulls Say
High-Value Solutions GrowthStrong growth in premium packaging and delivery platforms is improving mix and customer integration. Greater exposure to biologics and complex injectable therapies can support durable pricing, recurring programs, and higher-value revenue over the medium term.
Revenue And Margin ExpansionRevenue growth combined with faster EBITDA expansion indicates operating leverage and improving business quality. Management’s 2026 guidance for approximately 26.8% adjusted EBITDA margin suggests the benefits may persist as high-value products become a larger share of sales.
Strong Balance SheetModerate leverage and expanding equity provide financial resilience while the company funds capacity expansion. This capitalization supports investment in plants, equipment, and new delivery platforms without indicating excessive balance-sheet dependence.
Bears Say
Weak Free Cash Flow ConversionPersistent capital spending and working-capital needs are absorbing operating cash, leaving free cash flow volatile and currently negative. If this pattern continues, it could reduce funding flexibility and increase reliance on debt while major capacity projects mature.
Engineering Sales-Cycle RiskLonger qualification and project-timing cycles can delay equipment revenue and make the Engineering segment less predictable. Management expects a mid-single-digit to low-double-digit decline, creating an ongoing execution and mix risk despite improved margins.
Cost And Margin HeadwindsNew capacity increases depreciation and operating complexity, while utilities, currency, and taxation can limit underlying margin gains. These pressures may persist as the company scales its footprint, making sustained profitability improvement dependent on execution and mix.
Stevanato Group News
STVN FAQ
What was Stevanato Group Spa’s price range in the past 12 months?
Stevanato Group Spa lowest stock price was $12.89 and its highest was $28.00 in the past 12 months.
What is Stevanato Group Spa’s market cap?
Stevanato Group Spa’s market cap is $6.10B.
When is Stevanato Group Spa’s upcoming earnings report date?
Stevanato Group Spa’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Stevanato Group Spa’s earnings last quarter?
Stevanato Group Spa released its earnings results on Aug 04, 2026. The company reported $0.163 earnings per share for the quarter, beating the consensus estimate of $0.148 by $0.015.
Is Stevanato Group Spa overvalued?
According to Wall Street analysts Stevanato Group Spa’s price is currently Undervalued.
Does Stevanato Group Spa pay dividends?
Stevanato Group Spa pays a Annually dividend of $0.062 which represents an annual dividend yield of 0.28%. See more information on Stevanato Group Spa dividends here
What is Stevanato Group Spa’s EPS estimate?
Stevanato Group Spa’s EPS estimate is 0.18.
How many shares outstanding does Stevanato Group Spa have?
Stevanato Group Spa has 49,709,717 shares outstanding.
What happened to Stevanato Group Spa’s price movement after its last earnings report?
Stevanato Group Spa reported an EPS of $0.163 in its last earnings report, beating expectations of $0.148. Following the earnings report the stock price went down -4.565%.
Which hedge fund is a major shareholder of Stevanato Group Spa?
Currently, no hedge funds are holding shares in STVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (16.87% Upside)
$23.00 (16.87% Upside)
Blogger Sentiment
Bullish
STVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 544.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $370.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
0.28%
Trailing 12-Months
Asset Growth
8.48%
Trailing 12-Months
Company Description
Stevanato Group Spa
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
STVN Company Deck
STVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.View all STVN earnings summariesSTVN Stock 12 Month Forecast
Average Price Target
$23.00
▲(16.87% Upside)
Technical Analysis
Ownership Overview
2.76% Insiders
43.39% Mutual Funds
49.00% Other Institutional Investors
2.63% Public Companies and
Individual Investors